SimSon Pharma Limited is a privately held pharmaceutical reference materials and research chemicals company with over 12 years of operational history. The company’s corporate headquarters is located at The Platina Building, Dahisar East, Mumbai, Maharashtra, India, with its research and development laboratory situated at TSIIC, Kukatpally, Hyderabad, Telangana. The Hyderabad facility spans more than 50,000 square feet of laboratory infrastructure encompassing custom synthesis, purification and isolation, analytical testing, formulation R&D, microbiological testing, and quality assurance functions.

The company operates as part of the SimSon Group, which comprises four entities: SimSon Pharma Limited (pharmaceutical reference materials and research chemicals), SimSon Chemtech (industrial and specialty chemicals), SimSon Chemie (fine chemicals), and SimSon Pharma Services / SimSon Labs (CRO and analytical services). This group structure enables SimSon to position itself as a one-stop solution provider across chemical development, formulation development, analytical development, and regulatory services.

SimSon Pharma’s product range spans pharmaceutical reference standards, drug working standards, drug impurity standards, stable isotope labelled compounds, metabolites, and research chemicals synthesised to client specification. The company holds ISO 9001, ISO 14001, ISO 45001, GMP certification, NABL accreditation to ISO 17025 (testing), and ISO 17034 (reference material producer) — the latter being the internationally recognised accreditation for producers of certified reference materials. It holds a DSIR-recognised R&D laboratory designation and a valid drug licence. The company exports to clients across more than 120 countries and accepts orders via an e-commerce-enabled product portal with multilingual support across English, Chinese, Korean, Portuguese, Russian, Spanish, Italian, and Hebrew.

Key Products and Services

Reference Standards

• Pharmaceutical Reference Standards — primary and secondary reference standards for drug substances and finished pharmaceutical products, used for identification, assay, and pharmacopoeial testing purposes
• Working Standards — drug substance reference working materials derived from and traceable to primary reference standards, used for routine quality control analysis in pharmaceutical manufacturing

Impurity Standards

• Drug Impurity Standards — synthesis, characterisation, and supply of complex pharmaceutical impurities, including process-related impurities, degradation products, and genotoxic impurities, at high purity for use as reference standards in pharmaceutical analysis
• Nitrosamine Impurities — a dedicated portfolio of nitrosamine impurity reference standards in response to global regulatory requirements from the FDA, EMA, and ICH M7 guidelines; including nitrosodimethylamine (NDMA), nitrosodiethylamine (NDEA), and related N-nitrosamine compounds
• Unknown Impurity Identification — full-service identification, synthesis, and qualification of previously unknown impurities detected in pharmaceutical products or drug substance batches

Stable Isotope Labelled Compounds

• Deuterium-labelled compounds and other stable isotope labelled analogues (¹³C, ¹⁵N, ¹⁸O) of drug substances, impurities, and metabolites, used as internal standards in bioanalytical and pharmacokinetic studies, mass spectrometry-based quantitation, and metabolite profiling
• Complex isotope labelled compounds and metabolites, including labelled versions of complex molecules where isotope incorporation presents significant synthetic challenges

Metabolites

• Synthesis and supply of drug metabolites — the biotransformation products of drug substances in biological systems — used as reference standards for pharmacokinetic, bioanalytical, and safety testing studies

Peptide Impurities

• Reference standards for peptide-related impurities, supporting quality control and regulatory submissions for peptide drug substances and therapeutic peptides

Custom Synthesised Compounds

• Bespoke synthesis of complex organic molecules from milligram to kilogram scale, delivered by a team of PhD-qualified synthetic chemists with expertise in designing novel synthetic routes for both known and novel target compounds
• Scope spans small molecules, controlled substances, and complex natural product-derived structures

Research Chemicals

• Research-grade chemicals for laboratory use, synthesised to defined purity specifications for scientific and analytical research applications

Analytical Testing Services (via SimSon Pharma Services / SimSon Labs)

• In-house analytical testing using HPLC, GC, headspace GC, FTIR, LC-MS, ICP-MS, CHNSO, TGA, PSD, dissolution apparatus, and auto-titrators
• Bioanalytical standards and CRO services available via a dedicated contact channel

SimSon Pharma occupies a strategically important and technically demanding segment of the pharmaceutical supply chain: the manufacture and supply of certified reference materials and complex impurity standards. These materials are non-discretionary regulatory requirements for pharmaceutical manufacturers conducting ICH Q3A/Q3B impurity qualification, pharmacopoeial testing, and regulatory submissions, and their supply demands a combination of advanced synthetic chemistry, rigorous analytical characterisation, and certified reference material production infrastructure. SimSon’s dual NABL accreditation to both ISO 17025 (testing laboratory) and ISO 17034 (reference material producer) represents a meaningful quality credential in this segment, distinguishing it from unaccredited reference material suppliers. Its particular strength in complex impurity standards — including nitrosamine impurities, genotoxic impurities, and stable isotope labelled compounds — places it in a growing area of regulatory focus, as global health authorities have intensified scrutiny on nitrosamine contamination across multiple drug classes since 2018. With international reach across 120 countries and a group structure encompassing synthesis, fine chemicals, and CRO services, SimSon Pharma is positioned as a vertically integrated reference materials group with the ambition and infrastructure to compete with established European and North American reference standard suppliers in global pharmaceutical markets.